Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Up 22.9% in February

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) was the target of a large increase in short interest in February. As of February 15th, there was short interest totalling 2,310,000 shares, an increase of 22.9% from the January 31st total of 1,880,000 shares. Based on an average trading volume of 256,500 shares, the days-to-cover ratio is presently 9.0 days. Currently, 9.2% of the company’s stock are short sold.

Lexeo Therapeutics Stock Performance

LXEO traded down $0.11 during trading on Friday, hitting $2.71. The stock had a trading volume of 224,413 shares, compared to its average volume of 354,093. The firm has a market capitalization of $89.44 million, a P/E ratio of -0.86 and a beta of 3.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. Lexeo Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.50. The company’s 50-day moving average price is $5.06 and its 200 day moving average price is $7.51.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Frazier Life Sciences Management L.P. acquired a new position in shares of Lexeo Therapeutics during the 3rd quarter worth $11,307,000. Janus Henderson Group PLC increased its holdings in Lexeo Therapeutics by 18.9% in the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock valued at $33,997,000 after buying an additional 599,203 shares in the last quarter. Altium Capital Management LLC acquired a new stake in shares of Lexeo Therapeutics during the 4th quarter valued at approximately $2,665,000. Point72 Asset Management L.P. grew its holdings in shares of Lexeo Therapeutics by 102.5% in the 4th quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company’s stock worth $4,937,000 after acquiring an additional 379,828 shares during the period. Finally, Verition Fund Management LLC raised its holdings in Lexeo Therapeutics by 84.5% during the third quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock worth $7,027,000 after purchasing an additional 355,928 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

Wall Street Analyst Weigh In

LXEO has been the topic of several research analyst reports. HC Wainwright raised their target price on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. Leerink Partners reduced their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. Chardan Capital upped their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, January 21st. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $23.80.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.